Publication:
Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy

Placeholder

Departments

Organizational Unit

School / College / Institute

Organizational Unit
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU Authors

Co-Authors

Northend, Michael
Wilson, William
Clifton-Hadley, Laura
Rana, Zaynab
Martin, Tanya-Louise
Young, Moya
Miall, Fiona
Cunningham, David
Walewski, Jan
Johnston, Amanda

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Source

Publisher

American Society of Hematology (ASH)

Subject

Hematology

Citation

Has Part

Source

Blood

Book Series Title

Edition

DOI

10.1182/blood-2022-156790

item.page.datauri

Link

Rights

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

1

Views

0

Downloads

View PlumX Details